UK's GSK announces $30 billion U.S. pharma investment amid Trump state visitSkip NavigationMarketsPre-MarketsU.S. MarketsCurrenciesCryptocurrencyFutures & CommoditiesBondsFunds & ETFsBusinessEconomyFinanceHealth & ScienceMediaReal EstateEnergyClimateTransportationIndustrialsRetailWealthSportsLifeSmall BusinessInvestingPersonal FinanceFintechFinancial AdvisorsOptions ActionETF StreetBuffett ArchiveEarningsTrader TalkTechCybersecurityAIEnterpriseInternetMediaMobileSocial MediaCNBC Disruptor 50Tech GuidePoliticsWhite HousePolicyDefenseCongressExpanding OpportunityVideoLatest VideoFull EpisodesLivestreamLive AudioLive TV ScheduleCNBC PodcastsCEO InterviewsCNBC DocumentariesDigital OriginalsWatchlistInvesting ClubTrust PortfolioAnalysisTrade AlertsMeeting VideosHomestretchJim's ColumnsEducationSubscribePROPro NewsJosh BrownNEW!My PortfolioLivestreamFull EpisodesStock ScreenerMarket ForecastOptions InvestingChart InvestingStock ListsSubscribeLivestreamMenuMake ItselectUSAINTLLivestreamSearch quotes, news & videosLivestreamWatchlistSIGN INCreate free accountMarketsBusinessInvestingTechPoliticsVideoWatchlistInvesting ClubPROLivestreamMenuPharmaceuticalsUK's GSK announces $30 billion U.S. pharma investment amid Trump state visitPublished Wed, Sep 17 20252:29 AM EDTUpdated Wed, Sep 17 20255:10 AM EDTKaren Gilchrist@karengilchrist1@_karengilchristWATCH LIVEKey PointsGSK's investment will include $1.2 billion toward advanced manufacturing, AI and advanced digital technologies, the drug maker said.The investment commitment comes as President Donald Trump is in the U.K. for a three-day state visit.Major pharma firms have been piling into U.S. investments amid pressure from the Trump administration to bolster U.S. manufacturing and lower domestic drug prices. Rafael Henrique | Lightrocket | Getty ImagesBritain's GSK on Wednesday became the latest pharmaceutical firm to commit bumper investment into the U.S., as President Donald Trump is in the U.K. for a three-day state visit.The drug maker committed to investing at least $30 billion in U.S. research and developing (R&D) and manufacturing over the coming five years.The investment includes $1.2 billion toward advanced manufacturing, AI and advanced digital technologies to deliver "next-generation biopharma factories and laboratories in the United States," the drug maker said.The investment commitment comes as President Donald Trump is in the U.K. for a three-day state visit."This week's State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both," GSK CEO Emma Walmsley said in a statement."Today, we are committing to invest at least $30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country," she added.A number of global pharma firms have been ramping up their U.S. investments amid pressure from the Trump administration to bolster U.S. manufacturing and lower domestic drug prices.AstraZeneca in July announced plans to invest $50 billion in U.S. manufacturing and research capabilities by 2030, following a slew of commitments from companies including Novartis, Sanofi and Roche, and U.S.-headquartered Eli Lilly and Johnson & Johnson.GSK's $1.2 billion commitment to advanced manufacturing is set to include the construction of a new biologics factory in Pennsylvania to produce respiratory and cancer medicines, the company said, as well as the addition of advanced digital technology capabilities across GSK's existing five manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana.The wider funding is also due to go toward capital investments across GSK's U.S. supply chain and increased investment in R&D drug discovery and development and clinical trial activity, it added.Trump's state visit has turned out to be a lucrative affair, with a number of firms including Microsoft, Nvidia, Google, OpenAI and Salesforce this week announcing multibillion-dollar artificial intelligence investments in the U.K. in a symbol of strengthened transatlantic ties.Several pharma firms have nevertheless pulled or paused planned investments into the U.K., citing waning government support for the sector and a lack of movement on drug pricing. Subscribe to CNBC PROSubscribe to Investing ClubLicensing & ReprintsCNBC CouncilsSelect Personal FinanceCNBC on PeacockJoin the CNBC PanelSupply Chain ValuesClosed CaptioningDigital ProductsNews ReleasesInternshipsCorrectionsAbout CNBCAd ChoicesSite MapPodcastsCareersHelpContactNews TipsGot a confidential news tip? We want to hear from you.Get In TouchCNBC NewslettersSign up for free newsletters and get more CNBC delivered to your inboxSign Up NowGet this delivered to your inbox, and more info about our products and services.Advertise With UsPlease Contact UsPrivacy PolicyCA NoticeTerms of Service© 2025 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes.
Global Business and Financial News, Stock Quotes, and Market Data
and Analysis.
Market Data Terms of Use and DisclaimersData also provided by